MAN-01
Glaucoma
Pre-clinicalActive
Key Facts
About Q BioMed
Q BioMed operates as a development-stage biopharmaceutical company with a portfolio strategy aimed at de-risking the traditional drug development pathway. The company seeks to in-license or acquire promising biomedical assets, particularly small molecules, and advance them through clinical development and commercialization. Its approach is to create a pipeline spanning various therapeutic areas to share infrastructure costs and balance potential successes against failures. As a publicly traded entity, it aims to provide shareholder value by efficiently moving technologies toward monetization events.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| OMNI (Sustained Release Bimatoprost Implant) | Santen Pharmaceutical | Approved |
| Xelpros™ (latanoprost) | SPARC | Approved |
| INM-088 | InMed Pharmaceuticals | Preclinical |